Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Karp, JE; Kaufmann, SH; Adjei, AA; Lancet, JE; Wright, JJ; End, DW
   Current status of clinical trials of farnesyltransferase inhibitors
   CURRENT OPINION IN ONCOLOGY
   
   J.E. Karp et al., "Current status of clinical trials of farnesyltransferase inhibitors", CURR OPIN O, 13(6), 2001, pp. 470-476
2. Karp, JE
   MDR modulation in acute myelogenous leukemia: is it dead?
   LEUKEMIA
   
   J.E. Karp, "MDR modulation in acute myelogenous leukemia: is it dead?", LEUKEMIA, 15(4), 2001, pp. 666-667
3. Karp, JE; Lancet, JE; Kaufmann, SH; End, DW; Wright, JJ; Bol, K; Horak, I; Tidwell, ML; Liesveld, J; Kottke, TJ; Ange, D; Buddharaju, L; Gojo, I; Highsmith, WE; Belly, RT; Hohl, RJ; Rybak, ME; Thibault, A; Rosenblatt, J
   Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial
   BLOOD
   
   J.E. Karp et al., "Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial", BLOOD, 97(11), 2001, pp. 3361-3369
4. Brodsky, RA; Sensenbrenner, LL; Smith, BD; Dorr, D; Seaman, PJ; Lee, SM; Karp, JE; Brodsky, I; Jones, RJ
   Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia
   ANNALS OF INTERNAL MEDICINE
   
   R.A. Brodsky et al., "Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia", ANN INT MED, 135(7), 2001, pp. 477-483
5. Sarkodee-Adoo, CB; Merz, WG; Karp, JE
   Management of infections in patients with acute leukemia
   ONCOLOGY-NEW YORK
   
   C.B. Sarkodee-Adoo et al., "Management of infections in patients with acute leukemia", ONCOLOGY-NY, 14(5), 2000, pp. 659
6. Haga, SB; Fu, S; Karp, JE; Ross, DD; Williams, DM; Hankins, WD; Behm, F; Ruscetti, FW; Chang, M; Smith, BD; Becton, D; Raimondi, SC; Berg, PE
   BP1, a new homeobox gene, is frequently expressed in acute leukemias
   LEUKEMIA
   
   S.B. Haga et al., "BP1, a new homeobox gene, is frequently expressed in acute leukemias", LEUKEMIA, 14(11), 2000, pp. 1867-1875
7. Karp, JE; Sarkodee-Adoo, CB
   Therapy-related acute leukemia
   CLINICS IN LABORATORY MEDICINE
   
   J.E. Karp e C.B. Sarkodee-Adoo, "Therapy-related acute leukemia", CLIN LAB M, 20(1), 2000, pp. 71
8. Svingen, PA; Karp, JE; Krajewski, S; Mesner, PW; Gore, SD; Burke, PJ; Reed, JC; Lazebnik, YA; Kaufmann, SH
   Evaluation of Apaf-1 and procaspases-2,-3,-7,-8, and-9 as potential prognostic markers in acute leukemia
   BLOOD
   
   P.A. Svingen et al., "Evaluation of Apaf-1 and procaspases-2,-3,-7,-8, and-9 as potential prognostic markers in acute leukemia", BLOOD, 96(12), 2000, pp. 3922-3931
9. Ross, DD; Karp, JE; Chen, TT; Doyle, LA
   Expression of breast cancer resistance protein in blast cells from patients with acute leukemia
   BLOOD
   
   D.D. Ross et al., "Expression of breast cancer resistance protein in blast cells from patients with acute leukemia", BLOOD, 96(1), 2000, pp. 365-368
10. Samaniego, F; Bryant, JL; Liu, N; Karp, JE; Sabichi, AL; Thierry, A; Lunardi-Iskandar, Y; Gallo, RC
    Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin
    JOURNAL OF THE NATIONAL CANCER INSTITUTE
    
    F. Samaniego et al., "Induction of programmed cell death in Kaposi's sarcoma cells by preparations of human chorionic gonadotropin", J NAT CANC, 91(2), 1999, pp. 135-143
11. Karp, JE; Blattner, WA
    Immunosuppression, infection, and cancer
    MICROBES AND MALIGNANCY
    
    J.E. Karp e W.A. Blattner, "Immunosuppression, infection, and cancer", MICROBES AND MALIGNANCY, 1999, pp. 131-153
12. Karp, JE; Merz, WG
    Response: Randomized trial of lipid-based amphotericin B for invasive aspergillosis in neutropenic hosts is an important step forward
    CLINICAL INFECTIOUS DISEASES
    
    J.E. Karp e W.G. Merz, "Response: Randomized trial of lipid-based amphotericin B for invasive aspergillosis in neutropenic hosts is an important step forward", CLIN INF D, 27(6), 1998, pp. 1413-1414
13. KAUFMANN SH; GORE SD; MILLER CB; JONES RJ; ZWELLING LA; SCHNEIDER E; BURKE PJ; KARP JE
    TOPOISOMERASE-II AND THE RESPONSE TO ANTILEUKEMIC THERAPY
    Leukemia & lymphoma
    
    S.H. Kaufmann et al., "TOPOISOMERASE-II AND THE RESPONSE TO ANTILEUKEMIC THERAPY", Leukemia & lymphoma, 29(3-4), 1998, pp. 217-237
14. KAUFMANN SH; KARP JE; SVINGEN PA; KRAJEWSKI S; BURKE PJ; GORE SD; REED JC
    ELEVATED EXPRESSION OF THE APOPTOTIC REGULATOR MCL-1 AT THE TIME OF LEUKEMIC RELAPSE
    Blood
    
    S.H. Kaufmann et al., "ELEVATED EXPRESSION OF THE APOPTOTIC REGULATOR MCL-1 AT THE TIME OF LEUKEMIC RELAPSE", Blood, 91(3), 1998, pp. 991-1000
15. KAUFMANN SH; KARP JE; BURKE PJ; GORE SD
    ADDITION OF ETOPOSIDE TO INITIAL THERAPY OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A COMBINED CLINICAL AND LABORATORY STUDY (VOL 23, PG 71, PG 1996)
    Leukemia & lymphoma
    
    S.H. Kaufmann et al., "ADDITION OF ETOPOSIDE TO INITIAL THERAPY OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A COMBINED CLINICAL AND LABORATORY STUDY (VOL 23, PG 71, PG 1996)", Leukemia & lymphoma, 24(5-6), 1997, pp. 3-3
16. KARP JE
    ACUTE-LEUKEMIA - MECHANISMS OF CELL-SURVIVAL AS TARGETS FOR THERAPY (REVIEW)
    International journal of oncology
    
    J.E. Karp, "ACUTE-LEUKEMIA - MECHANISMS OF CELL-SURVIVAL AS TARGETS FOR THERAPY (REVIEW)", International journal of oncology, 11(4), 1997, pp. 657-674
17. KELLOFF GJ; HAWK ET; KARP JE; CROWELL JA; BOONE CW; STEELE VE; LUBET RA; SIGMAN CC
    PROGRESS IN CLINICAL CHEMOPREVENTION
    Seminars in oncology
    
    G.J. Kelloff et al., "PROGRESS IN CLINICAL CHEMOPREVENTION", Seminars in oncology, 24(2), 1997, pp. 241-252
18. KARP JE; SMITH MA
    THE MOLECULAR PATHOGENESIS OF TREATMENT-INDUCED (SECONDARY) LEUKEMIAS- FOUNDATIONS FOR TREATMENT AND PREVENTION
    Seminars in oncology
    
    J.E. Karp e M.A. Smith, "THE MOLECULAR PATHOGENESIS OF TREATMENT-INDUCED (SECONDARY) LEUKEMIAS- FOUNDATIONS FOR TREATMENT AND PREVENTION", Seminars in oncology, 24(1), 1997, pp. 103-113
19. BERG PE; HUGUENIN S; RUSCETTI FW; KARP JE; ROSS DD; HAGA S
    BP1, A NEW HOMEOBOX GENE, IS ABERRANTLY EXPRESSED IN ACUTE LEUKEMIAS
    Blood
    
    P.E. Berg et al., "BP1, A NEW HOMEOBOX GENE, IS ABERRANTLY EXPRESSED IN ACUTE LEUKEMIAS", Blood, 90(10), 1997, pp. 3670-3670
20. SOTOMAYOR EM; PIANTADOSI S; MILLER CB; KARP JE; KAUFMANN SH; BRAINE H; HUMPHREY RL; BURKE PJ; GORE SD
    LONG-TERM FOLLOW-UP OF INTENSIVE, ARA-C-BASED CHEMOTHERAPY FOLLOWED BY BONE-MARROW TRANSPLANTATION (BMT) FOR ADULT ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) - IMPROVED SURVIVAL WITH ALLOGENEIC, BUT NOT AUTOLOGOUS BMT
    Blood
    
    E.M. Sotomayor et al., "LONG-TERM FOLLOW-UP OF INTENSIVE, ARA-C-BASED CHEMOTHERAPY FOLLOWED BY BONE-MARROW TRANSPLANTATION (BMT) FOR ADULT ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) - IMPROVED SURVIVAL WITH ALLOGENEIC, BUT NOT AUTOLOGOUS BMT", Blood, 90(10), 1997, pp. 1484-1484
21. KAUFMANN SH; KARP JE; BURKE PJ; GORE SD
    ADDITION OF ETOPOSIDE TO INITIAL THERAPY OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A COMBINED CLINICAL AND LABORATORY STUDY
    Leukemia & lymphoma
    
    S.H. Kaufmann et al., "ADDITION OF ETOPOSIDE TO INITIAL THERAPY OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A COMBINED CLINICAL AND LABORATORY STUDY", Leukemia & lymphoma, 23(1-2), 1996, pp. 71-83
22. KARP JE; PLUDA JM; YARCHOAN R
    AIDS-RELATED KAPOSIS-SARCOMA - A TEMPLATE FOR THE TRANSLATION OF MOLECULAR PATHOGENESIS AND TARGETED THERAPEUTIC APPROACHES
    Hematology/oncology clinics of North America
    
    J.E. Karp et al., "AIDS-RELATED KAPOSIS-SARCOMA - A TEMPLATE FOR THE TRANSLATION OF MOLECULAR PATHOGENESIS AND TARGETED THERAPEUTIC APPROACHES", Hematology/oncology clinics of North America, 10(5), 1996, pp. 1031
23. KARP JE; CHIARODO A; BRAWLEY O; KELLOFF GJ
    PROSTATE-CANCER PREVENTION - INVESTIGATIONAL APPROACHES AND OPPORTUNITIES
    Cancer research
    
    J.E. Karp et al., "PROSTATE-CANCER PREVENTION - INVESTIGATIONAL APPROACHES AND OPPORTUNITIES", Cancer research, 56(24), 1996, pp. 5547-5556
24. SMITH MA; MCCAFFREY RP; KARP JE
    THE SECONDARY LEUKEMIAS - CHALLENGES AND RESEARCH DIRECTIONS
    Journal of the National Cancer Institute
    
    M.A. Smith et al., "THE SECONDARY LEUKEMIAS - CHALLENGES AND RESEARCH DIRECTIONS", Journal of the National Cancer Institute, 88(7), 1996, pp. 407-418
25. KARP JE; SMITH MA
    MODIFYING RISKS OF SECONDARY LEUKEMIAS - IS DRUG SCHEDULING IMPORTANT
    Journal of the National Cancer Institute
    
    J.E. Karp e M.A. Smith, "MODIFYING RISKS OF SECONDARY LEUKEMIAS - IS DRUG SCHEDULING IMPORTANT", Journal of the National Cancer Institute, 88(24), 1996, pp. 1787-1789
26. KARP JE; BRODER S
    MOLECULAR FOUNDATIONS OF CANCER - NEW TARGETS FOR INTERVENTION
    Nature medicine
    
    J.E. Karp e S. Broder, "MOLECULAR FOUNDATIONS OF CANCER - NEW TARGETS FOR INTERVENTION", Nature medicine, 1(4), 1995, pp. 309-320
27. BRODER S; KARP JE
    PROGRESS AGAINST CANCER
    Journal of cancer research and clinical oncology
    
    S. Broder e J.E. Karp, "PROGRESS AGAINST CANCER", Journal of cancer research and clinical oncology, 121(11), 1995, pp. 633-647
28. KAUFMANN SH; CHARRON M; BURKE PJ; KARP JE
    CHANGES IN TOPOISOMERASE-I LEVELS AND LOCALIZATION DURING MYELOID MATURATION IN-VITRO AND IN-VIVO
    Cancer research
    
    S.H. Kaufmann et al., "CHANGES IN TOPOISOMERASE-I LEVELS AND LOCALIZATION DURING MYELOID MATURATION IN-VITRO AND IN-VIVO", Cancer research, 55(6), 1995, pp. 1255-1260
29. SCHNEIDER E; COWAN KH; BADER H; TOOMEY S; SCHWARTZ GN; KARP JE; BURKE PJ; KAUFMANN SH
    INCREASED EXPRESSION OF THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN GENE IN RELAPSED ACUTE-LEUKEMIA
    Blood
    
    E. Schneider et al., "INCREASED EXPRESSION OF THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN GENE IN RELAPSED ACUTE-LEUKEMIA", Blood, 85(1), 1995, pp. 186-193
30. KARP JE; MERZ WG; DICK JD
    MANAGEMENT OF INFECTIONS IN NEUTROPENIC PATIENTS - NEW OPPORTUNITIES AND EMERGING CHALLENGES
    Current opinion in infectious diseases
    
    J.E. Karp et al., "MANAGEMENT OF INFECTIONS IN NEUTROPENIC PATIENTS - NEW OPPORTUNITIES AND EMERGING CHALLENGES", Current opinion in infectious diseases, 7(4), 1994, pp. 430-435
31. KARP JE; BRODER S
    ONCOLOGY AND HEMATOLOGY
    JAMA, the journal of the American Medical Association
    
    J.E. Karp e S. Broder, "ONCOLOGY AND HEMATOLOGY", JAMA, the journal of the American Medical Association, 271(21), 1994, pp. 1693-1695
32. KARP JE; BRODER S
    NEW DIRECTIONS IN MOLECULAR MEDICINE
    Cancer research
    
    J.E. Karp e S. Broder, "NEW DIRECTIONS IN MOLECULAR MEDICINE", Cancer research, 54(3), 1994, pp. 653-665
33. GELLER RB; KARP JE
    ADULT ACUTE-LEUKEMIA - A NEED FOR CONTINUED TRANSLATIONAL RESEARCH
    Blood
    
    R.B. Geller e J.E. Karp, "ADULT ACUTE-LEUKEMIA - A NEED FOR CONTINUED TRANSLATIONAL RESEARCH", Blood, 84(11), 1994, pp. 3980-3981
34. KAUFMANN SH; KARP JE; JONES RJ; MILLER CB; SCHNEIDER E; ZWELLING LA; COWAN K; WENDEL K; BURKE PJ
    TOPOISOMERASE-II LEVELS AND DRUG-SENSITIVITY IN ADULT ACUTE MYELOGENOUS LEUKEMIA
    Blood
    
    S.H. Kaufmann et al., "TOPOISOMERASE-II LEVELS AND DRUG-SENSITIVITY IN ADULT ACUTE MYELOGENOUS LEUKEMIA", Blood, 83(2), 1994, pp. 517-530
35. KARP JE; MCCAFFREY RP
    NEW AVENUES OF TRANSLATIONAL RESEARCH IN LEUKEMIA AND LYMPHOMA - OUTGROWTH OF A LEUKEMIA-SOCIETY-OF-AMERICA NATIONAL-CANCER-INSTITUTE WORKSHOP
    Journal of the National Cancer Institute
    
    J.E. Karp e R.P. Mccaffrey, "NEW AVENUES OF TRANSLATIONAL RESEARCH IN LEUKEMIA AND LYMPHOMA - OUTGROWTH OF A LEUKEMIA-SOCIETY-OF-AMERICA NATIONAL-CANCER-INSTITUTE WORKSHOP", Journal of the National Cancer Institute, 86(16), 1994, pp. 1196-1201
36. KARP JE; MERZ WG; DICK JD
    MANAGEMENT OF INFECTIONS IN NEUTROPENIC PATIENTS - ADVANCES IN THERAPY AND PREVENTION
    Current opinion in infectious diseases
    
    J.E. Karp et al., "MANAGEMENT OF INFECTIONS IN NEUTROPENIC PATIENTS - ADVANCES IN THERAPY AND PREVENTION", Current opinion in infectious diseases, 6(3), 1993, pp. 405-411
37. PLUDA JM; VENZON DJ; TOSATO G; LIETZAU J; WYVILL K; NELSON DL; JAFFE ES; KARP JE; BRODER S; YARCHOAN R
    PARAMETERS AFFECTING THE DEVELOPMENT OF NON-HODGKINS-LYMPHOMA IN PATIENTS WITH SEVERE HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION RECEIVING ANTIRETROVIRAL THERAPY
    Journal of clinical oncology
    
    J.M. Pluda et al., "PARAMETERS AFFECTING THE DEVELOPMENT OF NON-HODGKINS-LYMPHOMA IN PATIENTS WITH SEVERE HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION RECEIVING ANTIRETROVIRAL THERAPY", Journal of clinical oncology, 11(6), 1993, pp. 1099-1107
38. WINGARD JR; MERZ WG; RINALDI MG; MILLER CB; KARP JE; SARAL R
    ASSOCIATION OF TORULOPSIS-GLABRATA INFECTIONS WITH FLUCONAZOLE PROPHYLAXIS IN NEUTROPENIC BONE-MARROW TRANSPLANT PATIENTS
    Antimicrobial agents and chemotherapy
    
    J.R. Wingard et al., "ASSOCIATION OF TORULOPSIS-GLABRATA INFECTIONS WITH FLUCONAZOLE PROPHYLAXIS IN NEUTROPENIC BONE-MARROW TRANSPLANT PATIENTS", Antimicrobial agents and chemotherapy, 37(9), 1993, pp. 1847-1849
39. GORE SD; KARP JE; MILLER CB; BRAINE HL; HUMPHREY RL; KAUFMANN S; TUCKER RA; BURKE PJ
    BRIEF INTENSIVE THERAPY FOR ADULT ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) - SUPERIORITY OF ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)
    Blood
    
    S.D. Gore et al., "BRIEF INTENSIVE THERAPY FOR ADULT ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) - SUPERIORITY OF ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT)", Blood, 82(10), 1993, pp. 10000056-10000056
40. KARP JE
    STAT BITE - AIDS-RELATED CANCERS IN YOUNG WHITE MEN
    Journal of the National Cancer Institute
    
    J.E. Karp, "STAT BITE - AIDS-RELATED CANCERS IN YOUNG WHITE MEN", Journal of the National Cancer Institute, 85(14), 1993, pp. 1114-1114